McKesson Ventures
  • Portfolio
  • News
    • In the News
    • Press Releases
  • Team
  • About Us
    • Our Approach
    • About McKesson
    • Contact Us

Synthetic data trailblazer and CHEO Research Institute spin-off, Replica Analytics, acquired by Aetion signalling CHEO as a place for incubating start-ups

by McKesson Ventures | Mar 23, 2022 | Portfolio News

Synthetic data generation startup Replica Analytics was recently acquired by real world evidence technology company Aetion. Replica was first founded by members of the CHEO Research Institute and the University of Ottawa Faculty of Medicine. This acquisition...

Aetion Acquires Synthetic Data Trailblazer Replica Analytics

by McKesson Ventures | Jan 4, 2022 | Press Releases

Regulatory-grade real-world evidence technology provider Aetion recently announced its acquisition of Replica Analytics. Replica Analytics is well known for creating synthetic health data through artificial intelligence programs. Replica will be able to help Aetion...

European Medicines Agency Selects Aetion to Support Safety and Efficacy Research in Europe

by McKesson Ventures | Dec 1, 2021 | Press Releases

Aetion has been selected by the European Medicines Agency to support the agency’s Quality, Efficacy, and Safety Studies on Medicines. Aetion is a health care analytics company, working to provide real-world evidence for regulators, manufacturers, and purchasers of...

FDA Selects Aetion Evidence Platform® to Advance Regulatory Science and Innovation

by McKesson Ventures | Oct 21, 2021 | Press Releases

Aetion announced that it is expanding its relationship with the U.S. Food and Drug Administration to use real-world evidence to study COVID-19 interventions and advance regulatory science and innovation. The FDA and Aetion will use the Aetion Evidence Platform,...

Aetion and Quinten Health partner to use AI and RWE to reduce research timelines

by McKesson Ventures | Sep 22, 2021 | Press Releases

Aetion and Quinten Health have partnered up to better provide a range of real-world evidence (RWE) generation products and services by reducing complexity, increasing efficiency, and supporting rapid turnaround times to improve patient outcomes. Aetion Co-Founder and...
Page 2 of 6«12345...»Last »

Recent Posts

  • Lumata Health Secures $23 Million Series B to Expand Access and Adherence to Vision-Saving Care
  • Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials
  • Lynx Closes $27 Million Oversubscribed Series A, Aims to Revolutionize Healthcare Payments and Administration
  • HarmonyCares Announces 2023 Results for its High Needs REACH ACO
  • Reimagine Care and Memorial Hermann Health System Unveil Expanded On-Demand Cancer Care Partnership
McKesson Ventures

One Post Street, 21st Floor
San Francisco, CA 94104
USA

Contact Us

Cookie Settings

In the News

Reimagine Care and Memorial Hermann Health System Unveil Expanded On-Demand Cancer Care Partnership

HarmonyCares Secures $200M to Expand Access to In-Home Primary Care

ChatRWD™ Beta from Atropos Health Exceeds Big Tech LLMs on Physician Trust and Ability to Answer Questions Completely with High-Quality Evidence in New Study

Atropos Health Raises $33M To Scale The Automation Of High-Quality, Personalized Real-World Evidence Leveraging Generative AI

©2025 McKesson Ventures | Privacy Notice | Disclaimer
  • Follow
  • Follow